Sun Ying, Chang Zhiwen, Zhang Sujuan
Beijing Tong Ren Hospital, Capital Medical University, Beijing, PR China.
Arch Med Res. 2008 Apr;39(3):332-7. doi: 10.1016/j.arcmed.2007.11.009.
CXCL16 is a transmembrane molecule combining scavenger receptor functions with the properties of an inflammatory chemokine. Accumulating evidence suggests that CXCL16 is involved in atherosclerosis; however, the role of circulating soluble CXCL16 in human coronary artery disease remains unclear.
ELISA was used to examine the concentration of serum-soluble CXCL16 in 26 stable angina pectoris patients (SAP), 29 acute coronary syndrome (ACS) patients and 21 control patients.
In patients with ACS, serum level of CXCL16 was significantly increased compared to control and SAP patients (p <0.001 vs. control; p = 0.041 vs. SAP patients); serum levels of CXCL16 in patients with SAP were higher than in control patients although no statistical significance was found (p = 0.059). No significant association was found between serum CXCL16 and acute-phase reactants, TNF-alpha, or serum lipid parameters. In ACS patients, increased level of serum CXCL16 was not linked to either the severity of coronary stenosis or TIMI risk score, which is an early risk evaluation system for ACS.
Increased level of serum-soluble CXCL16 was independently associated with ACS.
CXCL16是一种跨膜分子，兼具清道夫受体功能和炎性趋化因子特性。越来越多的证据表明CXCL16参与动脉粥样硬化；然而，循环可溶性CXCL16在人类冠状动脉疾病中的作用仍不明确。
采用酶联免疫吸附测定法检测26例稳定型心绞痛患者（SAP）、29例急性冠状动脉综合征（ACS）患者及21例对照患者血清可溶性CXCL16浓度。
与对照患者和SAP患者相比，ACS患者血清CXCL16水平显著升高（与对照患者相比，p<0.001；与SAP患者相比，p = 0.041）；SAP患者血清CXCL16水平高于对照患者，但差异无统计学意义（p = 0.059）。血清CXCL16与急性期反应物、肿瘤坏死因子-α或血脂参数之间未发现显著关联。在ACS患者中，血清CXCL16水平升高与冠状动脉狭窄严重程度或心肌梗死溶栓治疗（TIMI）风险评分无关，TIMI风险评分是ACS的一种早期风险评估系统。
血清可溶性CXCL16水平升高与ACS独立相关。
